Literature DB >> 22538333

Metabolomic profile of human myocardial ischemia by nuclear magnetic resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models.

Vicente Bodi1, Juan Sanchis, Jose M Morales, Vannina G Marrachelli, Julio Nunez, Maria J Forteza, Fabian Chaustre, Cristina Gomez, Luis Mainar, Gema Minana, Eva Rumiz, Oliver Husser, Inmaculada Noguera, Ana Diaz, David Moratal, Arturo Carratala, Xavier Bosch, Angel Llacer, Francisco J Chorro, Juan R Viña, Daniel Monleon.   

Abstract

OBJECTIVES: The aim of this study was to investigate the metabolomic profile of acute myocardial ischemia (MIS) using nuclear magnetic resonance spectroscopy of peripheral blood serum of swine and patients undergoing angioplasty balloon-induced transient coronary occlusion.
BACKGROUND: Biochemical detection of MIS is a major challenge. The validation of novel biosignatures is of utmost importance.
METHODS: High-resolution nuclear magnetic resonance spectroscopy was used to profile 32 blood serum metabolites obtained (before and after controlled ischemia) from swine (n = 9) and patients (n = 20) undergoing transitory MIS in the setting of planned coronary angioplasty. Additionally, blood serum of control patients (n = 10) was sequentially profiled. Preliminary clinical validation of the developed metabolomic biosignature was undertaken in patients with spontaneous acute chest pain (n = 30).
RESULTS: Striking differences were detected in the blood profiles of swine and patients immediately after MIS. MIS induced early increases (10 min) of circulating glucose, lactate, glutamine, glycine, glycerol, phenylalanine, tyrosine, and phosphoethanolamine; decreases in choline-containing compounds and triacylglycerols; and a change in the pattern of total, esterified, and nonesterified fatty acids. Creatine increased 2 h after ischemia. Using multivariate analyses, a biosignature was developed that accurately detected patients with MIS both in the setting of angioplasty-related MIS (area under the curve 0.94) and in patients with acute chest pain (negative predictive value 95%).
CONCLUSIONS: This study reports, to the authors' knowledge, the first metabolic biosignature of acute MIS developed under highly controlled coronary flow restriction. Metabolic profiling of blood plasma appears to be a promising approach for the early detection of MIS in patients.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538333     DOI: 10.1016/j.jacc.2011.09.083

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  33 in total

Review 1.  Metabolomics in the diagnosis of acute myocardial ischemia.

Authors:  Vicente Bodi; Vannina G Marrachelli; Oliver Husser; Francisco J Chorro; Juan R Viña; Daniel Monleon
Journal:  J Cardiovasc Transl Res       Date:  2013-08-29       Impact factor: 4.132

2.  Inhomogeneity of collagen organization within the fibrotic scar after myocardial infarction: results in a swine model and in human samples.

Authors:  Arantxa Hervas; Amparo Ruiz-Sauri; Elena de Dios; Maria Jose Forteza; Gema Minana; Julio Nunez; Cristina Gomez; Clara Bonanad; Nerea Perez-Sole; Jose Gavara; Francisco Javier Chorro; Vicente Bodi
Journal:  J Anat       Date:  2015-10-29       Impact factor: 2.610

3.  Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension.

Authors:  Lin Piao; Yong-Hu Fang; Kishan Parikh; John J Ryan; Peter T Toth; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2013-06-21       Impact factor: 4.599

4.  Metabolic Intersection of Cancer and Cardiovascular Diseases: Opportunities for Cancer Therapy.

Authors:  Giang Hoang; Kiet Nguyen; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Bioengineering silicon quantum dot theranostics using a network analysis of metabolomic and proteomic data in cardiac ischemia.

Authors:  Folarin Erogbogbo; Jasmine May; Mark Swihart; Paras N Prasad; Katie Smart; Seif El Jack; Dariusz Korcyk; Mark Webster; Ralph Stewart; Irene Zeng; Mia Jullig; Katherine Bakeev; Michelle Jamieson; Nikolas Kasabov; Banu Gopalan; Linda Liang; Raphael Hu; Stefan Schliebs; Silas Villas-Boas; Patrick Gladding
Journal:  Theranostics       Date:  2013-09-04       Impact factor: 11.556

6.  Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine.

Authors:  Patrick A Gladding; Andrew Cave; Mehran Zareian; Kevin Smith; Jagir Hussan; Peter Hunter; Folarin Erogbogbo; Zoraida Aguilar; David S Martin; Eugene Chan; Margie L Homer; Abhijit V Shevade; Mohammad Kassemi; James D Thomas; Todd T Schlegel
Journal:  J Pers Med       Date:  2013-08-21

Review 7.  The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk.

Authors:  Matthew Nayor; Kemar J Brown; Ramachandran S Vasan
Journal:  Circ Res       Date:  2021-01-21       Impact factor: 17.367

8.  Differential effects of dry eye disorders on metabolomic profile by 1H nuclear magnetic resonance spectroscopy.

Authors:  Carmen Galbis-Estrada; Sebastián Martinez-Castillo; José M Morales; Bárbara Vivar-Llopis; Daniel Monleón; Manuel Díaz-Llopis; María Dolores Pinazo-Durán
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

9.  Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism.

Authors:  Aslan T Turer; Gregory D Lewis; John F O'Sullivan; Sammy Elmariah; Jessica L Mega; Tayo A Addo; Marc S Sabatine; James A de Lemos; Robert E Gerszten
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

10.  Genomic and metabolomic profile associated to microalbuminuria.

Authors:  Vannina G Marrachelli; Daniel Monleon; Pilar Rentero; María L Mansego; Jose Manuel Morales; Inma Galan; Remedios Segura; Fernando Martinez; Juan Carlos Martin-Escudero; Laisa Briongos; Pablo Marin; Gloria Lliso; Felipe Javier Chaves; Josep Redon
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.